JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan raised its Halozyme price target to $81 from $79 but kept a neutral rating; the target implies 12.84% downside from the stock’s prior close of $92.93.
  • Halozyme beat quarterly estimates, reporting EPS of $2.39 versus $2.30 expected and revenue of about $493 million; revenue rose 39.1% year over year.
  • Analyst views are mixed: MarketBeat’s consensus rating is “Hold,” with an average price target of $110.17.
  • MarketBeat previews top five stocks to own in December.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) had its price target boosted by stock analysts at JPMorgan Chase & Co. from $79.00 to $81.00 in a report released on Friday, Benzinga reports. The brokerage currently has a "neutral" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s target price would indicate a potential downside of 12.84% from the stock's previous close.

A number of other research analysts also recently issued reports on the company. Wall Street Zen downgraded Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 7th. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a report on Friday, October 16th. Leerink Partners cut Halozyme Therapeutics from an "outperform" rating to a "hold" rating and upped their price objective for the company from $110.00 to $117.00 in a research report on Friday, November 6th. Citigroup reiterated a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their price target for the company from $105.00 to $109.00 in a research report on Wednesday, November 11th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $110.17.

Read Our Latest Research Report on Halozyme Therapeutics

Halozyme Therapeutics Price Performance

NASDAQ HALO traded down $0.11 on Friday, hitting $92.93. The stock had a trading volume of 486,106 shares, compared to its average volume of 1,983,458. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. Halozyme Therapeutics has a 52-week low of $61.22 and a 52-week high of $134.00. The company has a market capitalization of $10.59 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 0.36 and a beta of 0.92. The firm has a 50-day moving average of $113.53 and a 200-day moving average of $85.96.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.09. The business had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. Halozyme Therapeutics's revenue for the quarter was up 39.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.72 earnings per share. Equities analysts expect that Halozyme Therapeutics will post 8.34 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $98.38, for a total value of $1,967,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $75,534,196.40. This represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the company's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the sale, the director owned 58,839 shares of the company's stock, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 149,226 shares of company stock valued at $15,744,643. 2.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth about $214,504,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at about $196,540,000. Congress Asset Management Co. increased its holdings in shares of Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock valued at $251,890,000 after purchasing an additional 1,052,509 shares during the period. Groupama Asset Managment acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at about $2,630,000. Finally, First Trust Advisors LP raised its stake in shares of Halozyme Therapeutics by 28.3% in the third quarter. First Trust Advisors LP now owns 1,817,824 shares of the biopharmaceutical company's stock worth $200,688,000 after purchasing an additional 400,761 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

More Halozyme Therapeutics News

Investors following HALO have been watching these news items:

  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $130 price target, signaling potential upside in the analyst’s view. HC Wainwright rating
  • Neutral Sentiment: A Halozyme director sold 5,000 shares under a pre-arranged Rule 10b5-1 trading plan; the scheduled nature of the sale makes it less clearly a signal about current prospects. Director share sale
  • Negative Sentiment: A German court overturned the preliminary injunction that had barred Merck from offering Keytruda SC in Germany. The ruling removes that immediate barrier to Merck’s product, raising concerns about Halozyme’s ability to enforce its patent and contributing to selling pressure. Halozyme says it will pursue a permanent patent case. Halozyme update on German court ruling

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Further Reading

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Halozyme Therapeutics Right Now?

Before you consider Halozyme Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.

While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines